Stock info GlaxoSmithKline | Filter  Basic-Info

Stock: GlaxoSmithKline (UK large caps), ISIN: US37733W1053

Last Price 1407.00 Max Price 1733.50
Min Price 1392.80 1 Year return -2.13
Avg. Target 0.00 Expected Return -100.00 %
Sector Health Care Subsector Pharmaceuticals
Sell 0 Rating
Hold 0 Concensus
Buy 0
Annual report 2012

GlaxoSmithKline (GSK) is a large research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. GlaxoSmithKline’s business employs approximately 100,000 people in 116 countries. GlaxoSmithKline’s stocks are traded in London and the company is a component of the FTSE 100-index (ISIN: GB0009252882/ Symbol: GSK).

Loading...

Contact info:Street: 980 Great West Road Zip Code: LondonCity: LondonCountry: Great BritainPhone: 44 (0)20 8047 5Email: in.investorqueries@gsk.comWebsite: www.gsk.com

Sector Review GlaxoSmithKline

Loading...
Year Turnover Total sector Market share
2019 33,754 615,634 5.48 %
2020 34,099 638,070 5.34 %
2021 34,114 727,968 4.69 %
2022 29,324 787,273 3.72 %
2023 0 0 0.00 %

Advice GlaxoSmithKline

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
June 10, 2023 Deutsche Bank GlaxoSmithKline Hold 1700.00 -1.97 %
January 05, 2023 Jefferies & Co. GlaxoSmithKline Buy 1575.00 3.47 %
January 03, 2023 JP Morgan GlaxoSmithKline Sell 1350.00 -7.38 %
November 08, 2022 JP Morgan GlaxoSmithKline Hold 1600.00 12.75 %
November 08, 2022 Barclays GlaxoSmithKline Hold 1450.00 3.72 %
June 05, 2022 Barclays GlaxoSmithKline Hold 1800.00 25.13 %
June 05, 2022 UBS GlaxoSmithKline Hold 1790.00 24.72 %
June 05, 2022 Deutsche Bank GlaxoSmithKline Hold 1750.00 22.99 %
April 27, 2022 Jefferies & Co. GlaxoSmithKline Buy 2100.00 29.81 %
December 20, 2021 Goldman Sachs GlaxoSmithKline Buy 2000.00 28.60 %
December 15, 2021 Goldman Sachs GlaxoSmithKline Buy 2000.00 27.75 %
December 15, 2021 Jefferies & Co. GlaxoSmithKline Buy 1925.00 24.94 %
November 07, 2021 Barclays GlaxoSmithKline Sell 1600.00 9.65 %
October 09, 2021 Morgan Stanley GlaxoSmithKline Hold 1555.00 15.14 %
September 26, 2021 UBS GlaxoSmithKline Hold 1460.00 10.10 %
August 27, 2021 UBS GlaxoSmithKline Hold 1540.00 9.16 %
August 21, 2021 JP Morgan GlaxoSmithKline Hold 1500.00 6.53 %
August 09, 2021 Goldman Sachs GlaxoSmithKline Buy 1870.00 10.86 %
August 03, 2021 UBS GlaxoSmithKline Hold 1485.00 -17.37 %
July 29, 2021 Barclays GlaxoSmithKline Sell 1350.00 -29.11 %
June 27, 2021 Kepler Capital Markets GlaxoSmithKline Hold 1500.00 -13.28 %
June 24, 2021 Credit Suisse GlaxoSmithKline Sell 1400.00 -21.37 %
June 24, 2021 Deutsche Bank GlaxoSmithKline Hold 1350.00 -25.87 %
June 22, 2021 Credit Suisse GlaxoSmithKline Sell 1300.00 -30.71 %
June 22, 2021 Barclays GlaxoSmithKline Sell 1250.00 -35.94 %
June 19, 2021 Goldman Sachs GlaxoSmithKline Buy 1800.00 4.88 %
June 14, 2021 Deutsche Bank GlaxoSmithKline Sell 1300.00 -34.69 %
June 06, 2021 UBS GlaxoSmithKline Hold 1370.00 -24.66 %
April 26, 2021 JP Morgan GlaxoSmithKline Hold 1300.00 -34.22 %
February 09, 2021 Jefferies & Co. GlaxoSmithKline Buy 1925.00 14.29 %
February 08, 2021 UBS GlaxoSmithKline Hold 1320.00 -25.00 %
February 05, 2021 Credit Suisse GlaxoSmithKline Sell 1400.00 -17.86 %
February 05, 2021 Goldman Sachs GlaxoSmithKline Buy 2010.00 17.91 %
February 05, 2021 Jefferies & Co. GlaxoSmithKline Buy 1950.00 15.38 %
February 05, 2021 UBS GlaxoSmithKline Hold 1450.00 -13.79 %
February 05, 2021 Oddo BHF GlaxoSmithKline Buy 1490.00 -17.52 %
February 04, 2021 Deutsche Bank GlaxoSmithKline Hold 1400.00 -17.86 %
February 03, 2021 KBC Securities GlaxoSmithKline Hold 1450.00 -20.76 %
January 20, 2021 Jefferies & Co. GlaxoSmithKline Buy 1950.00 12.42 %
December 16, 2020 DZ Bank GlaxoSmithKline Buy 1700.00 -3.00 %



News GlaxoSmithKline

GlaxoSmithKline and SK bioscience start late-stage trial for COVID-19 vaccine candidate

GlaxoSmithKline (NYSE:GSK) and SK bioscience announced the initiation of a global Phase 3 trial for GBP510, SK's COVID-19 vaccine candidate that uses the pandemic adjuvant from GSK. The randomized, active-controlled trial, expected to enroll about 4,000...

High dividend yield GlaxoSmithKline

Investors in GlaxoSmithKline can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the English market. Per share the analysts expect a dividend of 80 GBp per share. GlaxoSmithKline...

GlaxoSmithKline is one of the top English dividend stocks

Huge dividend GlaxoSmithKline Investors in GlaxoSmithKline can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the English market. For this year the analysts expect a dividend of80...

Analysts expect over 2019 rising revenue GlaxoSmithKline, quite high dividend

Tomorrow the English GlaxoSmithKline will report its past quarters results. Over the current book year the total revenue will be 31,79 billion GBp (consensus estimates). This is slightly more than 2017's revenue of 30,82 billion GBp. Historical revenues and results...

Analysts: more sales GlaxoSmithKline, high dividend yield

Over the current book year the total revenue will be 30,6 billion GBp (consensus estimates). This is slightly more than 2017's revenue of 30,19 billion GBp. Historical revenues and results GlaxoSmithKline plus estimates 2018 The analysts expect for 2018 a net...

Annual reports GlaxoSmithKline

2017 2018 2019 2020 2021

Profile GlaxoSmithKline

GlaxoSmithKline

(US37733W1053)/ GSKl

GlaxoSmithKline has located her head office London. GlaxoSmithKline's core business is the pharmaceutical sector. The global pharmaceutical companies gained around 75 percent over the period 2006-2016. Since 2011 the sector is 147 percent higher and over the past year minus 75 percent.

The past year was a profitable year for the GlaxoSmithKline investors

Over the past year the company' stock gained around 14 percent. Over the past 5 years GlaxoSmithKline' stock rose at around 7 percent in value. GlaxoSmithKline's revenues between 2011 and 2015 were relatively stable and moved between 2643,1 billion GBp and 2392,3 billion GBp. The net results between 2011 and 2015 were far from constant and fluctuated between 511,08 billion GBp and 269 billion GBp.

GlaxoSmithKline paid out dividends in the past 5 years. Over the past 5 years GlaxoSmithKline's dividend yield was at around 382 percent per year.

GlaxoSmithKline' balance mostly consists of equity

As per the end of 2015 the English company's balance sheet equaled 5344,6 billion GBp. The total debt was around 4833,2 billion GBp. This is 90,43 percent of the total balance sheet. At the end of 2016 the English company was traded with a price/earnings-ratio of around 24. So investors paid 24 times the company's 2015's EPS. Based on it's price/earnings-ratio and dividend yield the English stock can be seen as a value stock.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the pharmaceutical company equaled around 6539,82 billion GBp. At the end of 2015 the English company had around 4,83 billion stocks listed on the stock exchange(s).

All GlaxoSmithKline's annual reports can be found here. More information about GlaxoSmithKline can be found it's website. .


Results GlaxoSmithKline

Results
2015
2016
2017
2018
2019
2020
Revenue
23,923
27,889
30,186
30,821
33,754
34,099
Costs
15,501
26,976
28,654
27,198
29,109
28,350
Profit
8,422
913
1,532
3,623
4,645
5,749
Margin of profit
35.20
3.27
5.08
11.75
13.76
16.86
ROI
164.69
81.23
-2252.94
83.10
40.73
39.41

Balance GlaxoSmithKline

Balance
2015
2016
2017
2018
2019
2020
Equity
5,114
1,124
-68
4,360
11,405
14,587
Debt
48,332
57,957
56,449
53,706
68,287
65,844
Total assets
53,446
59,081
56,381
58,066
79,692
80,431
Solvency
9.57
1.90
-0.12
7.51
14.31
18.14
Cash
5,905
4,986
3,911
3,958
4,786
6,370
Cashflow
2,569
6,497
6,918
8,421
8,020
8,441
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.05
0.11
0.12
0.16
0.12
0.13

Details GlaxoSmithKline

Details
2016
2017
2018
2019
2020
Price
1367.34
1577.72
1335.81
1506.21
1796.90
Eps
0.23
0.39
0.91
1.16
1.43
Price/earnings-ratio
5944.96
4045.44
1467.92
1298.46
983.92
Dividend
1.00
1.00
1.00
1.00
1.00
Dividend %
0.07 %
0.06 %
0.07 %
0.07 %
0.07 %
Payout %
4.35
2.56
1.10
0.86
0.70
Book value
0.29
-0.02
1.11
2.88
3.63
Market to book
0.0
0.0
0.0
0.0
Cashflow per stock
1.65
1.74
2.14
2.02
2.10
Stocks
3,928
3,966
3,938
3,963
4,024
Market Cap
5.371.031.97
6.257.802.82
5.260.873.96
5.968.492.68
5.661.753.93

Dividend GlaxoSmithKline


Price info GlaxoSmithKline

Date
Price
31 Oct 2024
1407.00
29 Oct 2024
1452.00
23 Oct 2024
1453.50
19 Oct 2024
1476.00
16 Oct 2024
1496.00
14 Oct 2024
1494.50
05 Oct 2024
1459.50
02 Oct 2024
1521.50
27 Sep 2024
1522.00
20 Sep 2024
1574.50
17 Sep 2024
1632.00
13 Sep 2024
1638.50
28 Aug 2024
1618.00
26 Aug 2024
1602.50
23 Aug 2024
1597.00
11 Aug 2024
1565.50
07 Aug 2024
1535.00
05 Aug 2024
1547.00
01 Aug 2024
1512.00
30 Jul 2024
1557.00
26 Jul 2024
1523.50
23 Jul 2024
1524.50
16 Jul 2024
1498.00
10 Jul 2024
1505.00
09 Jul 2024
1509.50
04 Jul 2024
1503.50
02 Jul 2024
1595.00
26 Jun 2024
1595.00
21 Jun 2024
1733.50
19 Jun 2024
1733.50